Goldman Sachs’s Charles River Laboratories CRL Stock Holding History

Goldman Sachs’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,000	Closed	-$3.01M	–	6610
2021 Q4	$3.01M	Buy	+8,000	New	+$3.11M	﹤0.01%	3878
2021 Q3	–	Sell	-9,400	Closed	-$3.48M	–	6267
2021 Q2	$3.48M	Buy	+9,400	New	+$3.14M	﹤0.01%	3678
2017 Q3	–	Sell	-2,700	Closed	-$273K	–	6683
2017 Q2	$273K	Buy	+2,700	New	+$249K	﹤0.01%	5582
2014 Q2	–	Sell	-53,100	Closed	-$3.2M	–	6991
2014 Q1	$3.2M	Buy	53,100 +33,100	+166%	+$1.93M	﹤0.01%	3524
2013 Q4	$1.06M	Buy	+20,000	New	+$1M	﹤0.01%	4700
2013 Q3	–	Sell	-50,000	Closed	-$2.05M	–	6571
2013 Q2	$2.05M	Buy	+50,000	New	+$2.14M	﹤0.01%	3705

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Goldman Sachs's CRL Position: Q2 2026 in Review

Goldman Sachs increased its Charles River Laboratories (CRL) stake by 54% in Q2 2026, buying an estimated $40.1M and bringing the position to 639,803 shares worth $145M. The position accounts for 0.01% of the portfolio, ranked #952.

Goldman Sachs first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $150M in Q1 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Goldman Sachs held 639,803 shares of Charles River Laboratories worth $145M as of Q2 2026.
Goldman Sachs bought 225,075 Charles River Laboratories shares in Q2 2026, an estimated $40.1M.
Charles River Laboratories made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #952 holding.
Goldman Sachs first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
Goldman Sachs's Charles River Laboratories position peaked at $150M in Q1 2025.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.